Angion is a clinical stage biopharmaceutical company focused on acute kidney injury, a potentially life-threatening condition without therapeutic options. Our lead clinical asset, ANG-3777, is engineered to activate the HGF/c-MET pathway, an important mechanism in organ repair.
Angion is developing ANG-3777 to potentially meet the high unmet medical need of acute kidney injury resulting from kidney transplantation and from cardiac surgery. We are currently conducting Phase 2 and Phase 3 clinical trials with improvement in kidney function as an endpoint.
Angion’s robust pipeline includes ANG-3070, an oral small molecule in development as a potential treatment for fibrosis and other severe organ damage.
– – – Angion scientists also present research advancing t
UNIONDALE, N.Y. November 4, 2019 — Angion Biomedica Corp. (Angion), a